Cytotoxicity, Immunologic

"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.

Descriptor ID	D003602
MeSH Number(s)	G12.287
Concept/Terms	Cytotoxicity, Immunologic Cytotoxicity, Immunologic Immunologic Cytotoxicity Immunologic Tumoricidal Activities Immunologic Tumoricidal Activities Tumoricidal Activities, Immunologic Tumoricidal Activity, Immunologic Immunologic Tumoricidal Activity

Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".

Biological Sciences [G]
Immune System Phenomena [G12]
Cytotoxicity, Immunologic [G12.287]

Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in this website by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publications.

Bar chart showing 49 publications over 22 distinct years, with a maximum of 4 publications in 1996 and 2002 and 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	3	4
1997	2	0	2
1998	1	0	1
2000	1	1	2
2001	1	2	3
2002	1	3	4
2003	0	3	3
2004	1	0	1
2005	1	1	2
2006	1	0	1
2007	2	1	3
2008	1	2	3
2009	2	0	2
2010	0	1	1
2011	1	3	4
2012	1	1	2
2013	1	0	1
2014	0	3	3
2017	1	1	2
2018	1	1	2
2019	1	1	2
2021	0	1	1

Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.

Knudson CJ, F?rez M, Alves-Peixoto P, Erkes DA, Melo-Silva CR, Tang L, Snyder CM, Sigal LJ. Mechanisms of Antiviral Cytotoxic CD4 T Cell Differentiation. J Virol. 2021 09 09; 95(19):e0056621.

View in: PubMed
Kundu K, Ghosh S, Sarkar R, Edri A, Brusilovsky M, Gershoni-Yahalom O, Yossef R, Shemesh A, Soria JC, Lazar V, Joshua BZ, Campbell KS, Elkabets M, Porgador A. Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA. Cancer Immunol Res. 2019 07; 7(7):1120-1134.

View in: PubMed
Forsyth KS, Addison MM, Eisenlohr LC. Recombinant Poxviruses: Versatile Tools for Immunological Assays. Methods Mol Biol. 2019; 1988:217-248.

View in: PubMed
Magee MS, Abraham TS, Baybutt TR, Flickinger JC, Ridge NA, Marszalowicz GP, Prajapati P, Hersperger AR, Waldman SA, Snook AE. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res. 2018 05; 6(5):509-516.

View in: PubMed
Tario JD, Conway AN, Muirhead KA, Wallace PK. Monitoring Cell Proliferation by Dye Dilution: Considerations for Probe Selection. Methods Mol Biol. 2018; 1678:249-299.

View in: PubMed
Shemesh A, Brusilovsky M, Kundu K, Ottolenghi A, Campbell KS, Porgador A. Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints. Cancer Immunol Immunother. 2018 Dec; 67(12):1871-1883.

View in: PubMed
Xiang B, Baybutt TR, Berman-Booty L, Magee MS, Waldman SA, Alexeev VY, Snook AE. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells. J Immunol. 2017 05 01; 198(9):3507-3514.

View in: PubMed
Purdy AK, Alvarez Arias DA, Oshinsky J, James AM, Serebriiskii I, Campbell KS. The ap-2 clathrin adaptor mediates endocytosis of an inhibitory killer cell Ig-like receptor in human NK cells. J Immunol. 2014 Nov 01; 193(9):4675-83.

View in: PubMed
Anikeeva N, Steblyanko M, Fayngerts S, Kopylova N, Marshall DJ, Powers GD, Sato T, Campbell KS, Sykulev Y. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity. Eur J Immunol. 2014 Aug; 44(8):2331-9.

View in: PubMed
Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement